Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Cencora, Inc.. A complete text table follows the diagram.
Enormous pharmaceutical throughput produces a thin gross-profit pool, while OneOncology pushes the model downstream toward physicians and patients
Swipe to explore
The primary diagram begins at segment gross profit rather than revenue because pharmaceutical acquisition cost is a large pass-through and obscures the economic engines. Segment operating-expense nodes are directly reported. The diagram reconciles to operating income; the separate $1,086.612M OneOncology remeasurement gain that lifted pretax and net income is disclosed in annotations rather than treated as recurring operations.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| U.S. Healthcare gross profit | 1 | $2.3B | $68.77B of drug and specialty throughput |
| International Healthcare gross profit | 1 | $814M | Alliance Healthcare and other international services |
| Animal Health & other gross profit | 1 | $312M | Animal health plus non-strategic businesses |
| U.S. Healthcare operating income | 2 | $998M | 44.3% conversion of segment gross profit |
| U.S. platform operating expense | 2 | $1.3B | Distribution, specialty services and support |
| International operating income | 2 | $176M | 21.6% conversion of segment gross profit |
| International operating expense | 2 | $638M | European and global distribution platform |
| Animal Health & other income | 2 | $91.6M | 29.4% conversion of segment gross profit |
| Animal Health & other expense | 2 | $220M | Operating cost of adjacent businesses |
| Operating income before eliminations | 3 | $1.3B | U.S. Healthcare supplies 79% |
| Reported segment operating income | 4 | $1.3B | After intersegment eliminations |
| Intersegment eliminations | 4 | $2.4M | Reported segment-income adjustment |
| LIFO credit & antitrust settlements | 4 | $227M | Positive operating reconciliation |
| Operating income before special charges | 5 | $1.5B | Segments plus positive reported items |
| GAAP operating income | 6 | $1.1B | Up 10% year over year |
| Acquisition, litigation & other charges | 6 | $347M | Amortization, integration, opioids and restructuring |
| From | To | Value |
|---|---|---|
| U.S. Healthcare gross profit | U.S. Healthcare operating income | $998M |
| U.S. Healthcare gross profit | U.S. platform operating expense | $1.3B |
| International Healthcare gross profit | International operating income | $176M |
| International Healthcare gross profit | International operating expense | $638M |
| Animal Health & other gross profit | Animal Health & other income | $91.6M |
| Animal Health & other gross profit | Animal Health & other expense | $220M |
| U.S. Healthcare operating income | Operating income before eliminations | $998M |
| International operating income | Operating income before eliminations | $176M |
| Animal Health & other income | Operating income before eliminations | $91.6M |
| Operating income before eliminations | Reported segment operating income | $1.3B |
| Operating income before eliminations | Intersegment eliminations | $2.4M |
| Reported segment operating income | Operating income before special charges | $1.3B |
| LIFO credit & antitrust settlements | Operating income before special charges | $227M |
| Operating income before special charges | GAAP operating income | $1.1B |
| Operating income before special charges | Acquisition, litigation & other charges | $347M |